DK0574313T3 - 1,4-disubstituerede piperaziner til behandling af sygdomme i centralnervesystemet og neuroendocrine sygdomme - Google Patents

1,4-disubstituerede piperaziner til behandling af sygdomme i centralnervesystemet og neuroendocrine sygdomme

Info

Publication number
DK0574313T3
DK0574313T3 DK93401476T DK93401476T DK0574313T3 DK 0574313 T3 DK0574313 T3 DK 0574313T3 DK 93401476 T DK93401476 T DK 93401476T DK 93401476 T DK93401476 T DK 93401476T DK 0574313 T3 DK0574313 T3 DK 0574313T3
Authority
DK
Denmark
Prior art keywords
treatment
nervous system
central nervous
disubstituted piperazines
neuroendocrine disorders
Prior art date
Application number
DK93401476T
Other languages
English (en)
Inventor
Jean-Louis Peglion
Bertrand Goument
Mark Millan
Jean-Michel Rivet
Original Assignee
Adir
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adir filed Critical Adir
Application granted granted Critical
Publication of DK0574313T3 publication Critical patent/DK0574313T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DK93401476T 1992-06-12 1993-06-10 1,4-disubstituerede piperaziner til behandling af sygdomme i centralnervesystemet og neuroendocrine sygdomme DK0574313T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR929207065A FR2692264B1 (fr) 1992-06-12 1992-06-12 Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les contenant.

Publications (1)

Publication Number Publication Date
DK0574313T3 true DK0574313T3 (da) 2000-04-03

Family

ID=9430639

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93401476T DK0574313T3 (da) 1992-06-12 1993-06-10 1,4-disubstituerede piperaziner til behandling af sygdomme i centralnervesystemet og neuroendocrine sygdomme

Country Status (13)

Country Link
US (1) US5464834A (da)
EP (1) EP0574313B1 (da)
JP (1) JP2634370B2 (da)
AT (1) ATE185345T1 (da)
AU (1) AU658512B2 (da)
CA (1) CA2098252A1 (da)
DE (1) DE69326637T2 (da)
DK (1) DK0574313T3 (da)
ES (1) ES2139638T3 (da)
FR (1) FR2692264B1 (da)
GR (1) GR3031492T3 (da)
NZ (1) NZ247854A (da)
ZA (1) ZA934143B (da)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9125900D0 (en) * 1991-12-05 1992-02-05 Wyeth John & Brother Ltd Piperazine derivatives
GB9308725D0 (en) * 1993-04-27 1993-06-09 Wyeth John & Brother Ltd Piperazine derivatives
FR2734819B1 (fr) * 1995-05-31 1997-07-04 Adir Nouveaux composes de la piperazine, de la piperidine et de la 1,2,5,6-tetrahydropyridine, leur procede de preparation et les compositions pharmaceutiques les contenant
US6156057A (en) * 1995-08-12 2000-12-05 Fox; James Allan Method for inducing hypothermia
JPH09124643A (ja) * 1995-08-14 1997-05-13 Bristol Myers Squibb Co 抗うつ作用を有する１−アリールアルキル−４−（アルコキシピリジニル）−又は４−（アルコキシピリミジニル）ピペラジン誘導体
FR2738823B1 (fr) * 1995-09-15 1997-10-31 Synthelabo Derives de 3-(omega-(4-(thieno(3,2-c)pyridin-4-yl)piperazin- 1-yl)alkyl)-3,4-dihydroquinolein-2(1h)-one,leur preparation et leur application en therapeutique
US5990114A (en) * 1996-02-28 1999-11-23 Recordati, S.A., Chemical And Pharmaceutical Company Use of 5-HT1A receptor antagonists for the treatment of urinary incontinence
US6090132A (en) * 1996-08-15 2000-07-18 Fox; James Allan Method and apparatus for inducing hypothermia
ATE246683T1 (de) * 1996-12-20 2003-08-15 Lundbeck & Co As H Indan- oder dihydroindol-derivate
US6436940B2 (en) 1996-12-20 2002-08-20 H. Lundbeck A/S Indane or dihydroindole derivatives
FR2761358B1 (fr) * 1997-03-27 1999-05-07 Adir Nouveaux composes de n-aryl piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
ES2128266B1 (es) 1997-07-08 2000-01-16 Vita Invest Sa Compuestos derivados de tiofeno y benzotiofeno y utilizacion y composicion correspondientes.
AR013206A1 (es) * 1997-07-25 2000-12-13 Lundbeck & Co As H Derivados indol y 2,3-dihidroindol, composiciones farmaceuticas que contienen estos compuestos y el uso de dichos compuestos para la preparacion de un medicamento para el tratamiento de desordenes sensibles a la inhibicion de la reabsorcion de serotonina y antagonismo de receptores 5-ht1a.
JP2003524571A (ja) 1997-07-25 2003-08-19 ハー・ルンドベック・アクチエゼルスカベット インドール−及び２，３−ジヒドロインドール誘導体、その製造方法及びその使用方法
TW530054B (en) 1997-09-24 2003-05-01 Duphar Int Res New piperazine and piperidine compounds
FR2769312B1 (fr) * 1997-10-03 1999-12-03 Adir Nouveaux composes de l'indanol, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU9810498A (en) * 1997-10-24 1999-05-17 Neurogen Corporation 1-(2-naphthyl) and 1-(2-azanaphthyl)-4 -(1-phenylmethyl)piperazines being dopamine d4 receptor subtyp e ligands
US6040448A (en) 1997-10-24 2000-03-21 Neurogen Corporation Certain 1-(2-naphthyl) and 1-(2-azanaphthyl)-4-(1-phenylmethyl) piperazines, dopamine receptor subtype specific ligands
US6177566B1 (en) 1998-06-30 2001-01-23 Neurogen Corporation 6-(4-arylalkylpiperazin-1-yl) benzodioxane and 6-(4-arylalkylpiperazin-1-yl) chromane derivatives: dopamine receptor subtype specific ligands
AR022303A1 (es) * 1999-01-22 2002-09-04 Lundbeck & Co As H Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion
PT1113015E (pt) * 1999-12-29 2004-12-31 Pfizer Prod Inc Compostos 3-((2-piperazinilfenil)metil)-1-(4-(trifluorometil)fenil)-2-pirrolidinona opticamente activos, como antagonistas selectivos dos receptores de 5-ht1d
ES2188344B1 (es) * 2000-11-29 2004-09-16 Laboratorios Vita, S.A. Compuestos derivados de benzotiofeno, su procedimiento de obtencion y utilizacion de los mismos.
US7504395B2 (en) * 2001-07-20 2009-03-17 Psychogenics, Inc. Treatment for attention-deficit hyperactivity disorder
US20060122177A1 (en) * 2004-12-07 2006-06-08 Solvay Pharmaceuticals B.V. Phenylpiperazines with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites
US7371769B2 (en) * 2004-12-07 2008-05-13 Solvay Pharmaceuticals B.V. Tetrahydropyridin-4-yl indoles with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites
US20070072870A2 (en) * 2004-12-08 2007-03-29 Solvay Pharmeceuticals B.V. Phenylpiperazine derivatives with a combination of partial dopamine-d2 receptor agonism and serotonin reuptake inhibition
KR20070085988A (ko) * 2004-12-08 2007-08-27 솔베이 파마슈티칼스 비. 브이 부분 도파민-ｄ2 수용체 작용성과 세로토닌 재흡수억제성이 조합된 페닐피페라진 유도체
FR2884251B1 (fr) * 2005-04-08 2007-07-13 Servier Lab Derives de piperazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2909670B1 (fr) * 2006-12-12 2010-07-30 Sanofi Aventis Derive fluore de quinoleine-2(1h)-one,son procede de preparation et son utilisation comme intermediaire de synthese
CN104193761B (zh) 2009-12-04 2017-10-17 桑诺维恩药品公司 多环化合物及其使用方法
SG10202100724UA (en) 2016-07-29 2021-03-30 Sunovion Pharmaceuticals Inc Compounds and compositions and uses thereof
BR112019001407A2 (pt) 2016-07-29 2019-07-09 Sunovion Pharmaceuticals Inc. compostos e composições e usos dos mesmos
EP3582815A1 (en) 2017-02-16 2019-12-25 Sunovion Pharmaceuticals Inc. Methods of treating schizophrenia
MX2020000523A (es) 2017-08-02 2020-08-20 Sunovion Pharmaceuticals Inc Compuestos de isocromano y usos de los mismos.
US10944465B2 (en) * 2017-08-09 2021-03-09 Telefonaktiebolaget Lm Ericsson (Publ) System and method for antenna beam selection
SG11202007823PA (en) 2018-02-16 2020-09-29 Sunovion Pharmaceuticals Inc Salts, crystal forms, and production methods thereof
JP7703449B2 (ja) 2019-03-14 2025-07-07 スミトモ・ファーマ・アメリカ・インコーポレイテッド イソクロマニル化合物の塩およびその結晶体、ならびにそれらの製造方法、治療用途および医薬組成物
KR20230003503A (ko) 2020-04-14 2023-01-06 선오비온 파마슈티컬스 인코포레이티드 신경학적 및 정신의학적 장애의 치료를 위한 (S)-(4,5-디히드로-7H-티에노[2,3-c]피란-7-일)-N-메틸메탄아민
CN113896709B (zh) * 2021-11-22 2023-02-28 南京一苇医药科技有限公司 一种苯并噻吩-3-乙酸的合成方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2037852C3 (de) * 1970-07-30 1980-06-26 Boehringer Sohn Ingelheim Neue Piperazinderivate und Verfahren zu ihrer Herstellung
US4335126A (en) * 1977-03-10 1982-06-15 Degussa Aktiengesellschaft 1-[3-(3,4,5-Trimethoxyphenoxy)-2-hydroxy-propyl]-4-aryl-piperazine-derivatives having pharmaceutical activity
FR2515647A1 (fr) * 1981-11-03 1983-05-06 Cortial Nouvelles imines derivees de (phenyl-4 piperazinylethyl)-2 anilines, leur methode de preparation et leur application therapeutique
EP0185429A1 (en) * 1984-12-21 1986-06-25 Duphar International Research B.V New bicyclic heteroaryl piperazines
DK93087A (da) * 1986-02-27 1987-08-28 Duphar Int Res Hidtil ukendte aryl substituerede (n-piperidinyl)methyl- og (n-piperazinyl)methylazoler med antipsykotiske egenskaber
JPH01113377A (ja) * 1987-10-23 1989-05-02 Yoshitomi Pharmaceut Ind Ltd ピペラジン化合物
GB8830312D0 (en) * 1988-12-28 1989-02-22 Lundbeck & Co As H Heterocyclic compounds
FR2670491B1 (fr) * 1990-12-14 1993-02-05 Adir Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les renfermant.
DE4127849A1 (de) * 1991-08-22 1993-02-25 Merck Patent Gmbh Benzodioxanderivate

Also Published As

Publication number Publication date
ZA934143B (en) 1994-01-17
US5464834A (en) 1995-11-07
EP0574313B1 (fr) 1999-10-06
JPH06179670A (ja) 1994-06-28
DE69326637T2 (de) 2000-05-18
GR3031492T3 (en) 2000-01-31
JP2634370B2 (ja) 1997-07-23
NZ247854A (en) 1994-09-27
AU658512B2 (en) 1995-04-13
ES2139638T3 (es) 2000-02-16
CA2098252A1 (fr) 1993-12-13
FR2692264A1 (fr) 1993-12-17
EP0574313A1 (fr) 1993-12-15
DE69326637D1 (de) 1999-11-11
ATE185345T1 (de) 1999-10-15
FR2692264B1 (fr) 1994-08-05
AU4017893A (en) 1993-12-16

Similar Documents

Publication Publication Date Title
GR3031492T3 (en) 1,4-Disubstituted piperazines for the treatment of disorders of the central nervous system and neuro-endocrine disorders
ATE125537T1 (de) 1,4-disubstituierte piperazine, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen.
UA27749C2 (uk) Заміщені циклопропіламіно-1,3,5-триазини, їх оптичні ізомери, рацемічні суміші чи їх солі приєднання нетоксичних фармацевтично прийнятних кислот, що мають фармакологічну активність, спосіб їх одержання (варіанти) та фармацевтична композиція на їх основі
DE69106365D1 (de) Chinuclidinderivate.
IS1904B (is) Hliðstæðar aðferðir við framleiðslu á nýjum (R)-5-karbamóýl-8-flúor-3-N,N-tvíútskiptum-amínó-3,4-díhýdró-2H-1-bensópýrönum
DK164937C (da) Analogifremgangsmaade til fremstilling af 1-alkyl-2-aminotetralinderivater eller farmaceutisk acceptable syreadditionssalte deraf samt 1-alkyl-2-aminotetralinderivater til anvendelse som udgangsmateriale i fremgangsmaaden
NO180632C (no) 1,3-substituerte cykloalkener og cykloalkaner som sentralnervesystem-midler
DE69216293D1 (de) 1,4-Disubstituierte Piperidinderivate, ihre Herstellung und therapeutische Verwendung
ATE122042T1 (de) Pyrazoloisoquinoline-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen.
PT783495E (pt) Derivados de quinoxalina uteis em terapia
DE69414194D1 (de) Aminosäurederivate und ihre Verwendung als Enkephalinase-Inhibitoren
ATE123776T1 (de) Aminoalkylchromone, verfahren zu ihrer herstellung und diese enthaltende zusammensetzungen.
ATE56705T1 (de) Piperidinderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate.
DK0518769T3 (da) Hidtil ukendte ethanolaminbenzoatderivater, fremgangsmåde til fremstilling heraf og farmaceutiske midler, som indeholder dem.
ATE138805T1 (de) Substituiertes benzofuranylpiperidin als nootropikum